April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
An Original Administration Of Oral Pilocarpine (Salagen® Tablet 5mg) For Dry Eye
Author Affiliations & Notes
  • Tatsuro Miyamoto
    Ophthalmology, Tokushima University, Tokushima, Japan
  • Hiroshi Eguchi
    Ophthalmology, Tokushima University, Tokushima, Japan
  • Yoshinori Mitamura
    Ophthalmology, Tokushima University, Tokushima, Japan
  • Footnotes
    Commercial Relationships  Tatsuro Miyamoto, None; Hiroshi Eguchi, None; Yoshinori Mitamura, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3835. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tatsuro Miyamoto, Hiroshi Eguchi, Yoshinori Mitamura; An Original Administration Of Oral Pilocarpine (Salagen® Tablet 5mg) For Dry Eye. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3835.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the efficacy of 10mg oral pilocarpine (Salagen® Tab. 5mg) administration given fouth daily to the patients with Sjögren syndrome.

Methods: : Four cases of dry eye patients were randomized to receive 10mg oral pilocarpine given fourth daily. Two cases were changed from previous medication. Another two cases were initially administrated 10mg oral pilocarpine given fourth daily. All cases were female. To assess the efficacy, Shirmer’s-1 test, break up time test (BUT), fluorescein stain score, and subjective symptoms were evaluated at each stage in changing the administration and compared with two cases administrated one tablet pilocarpine once daily in initiating the administration.

Results: : In a patient, Shirmer’s-1 test, BUT, and fluorescein stain score at 10mg oral pilocarpine administration given fourth daily were changed 14.5mm, 7sec,and 1 from 17.5mm, 6sec, and 4 at 15mg administration third a day. In another patient, Shirmer’s-1 test, BUT, and fluorescein stain score at 10mg oral pilocarpine administration given fourth daily were changed 2.5mm, 3sec, 3 from 1mm, 3sec, and 2 at 10mg oral pilocarpine administration given twice daily. Foreign body sensation was improved and palpitation and gastric discomfort were diminished by changing 10mg administration given fourth daily from the previous therapy. Shirmer’s-1 test of initial 10mg administrated patients and control group is 6.8±1.9mm, 5.8±3.2mm at baseline and 5.5±1.9 mm, 7.8±4.3mm in 1 month of administration. BUT is 2.3 ±0.5sec, 1.0±0.0sec at baseline and 4.0±0.8sec, 3.5±1.0sec in 1month of administration. Fluorescein stain score is 2.5±1.0, 3.0±2.0 at baseline and 1.3±0.5, 2.3±1.5 in 1 month of administration. Subjective symptoms were better in the group of 10mg administration than in the control group.

Conclusions: : 10mg oral pilocarpine administration given fourth daily has the possibility to control dry eye with Sjögren syndrome.

Clinical Trial: : http://www.umin.ac.jp/, UMIN000002200

Keywords: cornea: tears/tear film/dry eye 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×